1.4469

1.04% -0.0069

Scienture Holdings Inc (SCNX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$1.44

Offen:

$1.43

24-Stunden-Volumen:

68,291

Relative Volume:

0.03

Marktkapitalisierung:

$12.95M

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

EPS:

Netto-Cashflow:

1W Leistung:

-19.49%

1M Leistung:

-46.23%

6M Leistung:

-80.45%

1J Leistung:

+0.00%

1-Tages-Spanne:

$1.3718

$1.48

1-Wochen-Bereich:

$1.17

$1.88

52-Wochen-Spanne:

$1.00

$9.55

Scienture Holdings Inc Stock (SCNX) Company Profile

Firmenname

Scienture Holdings Inc

Sektor

Healthcare (1165)

Branche

Pharmaceutical Retailers (9)

Telefon

(800) 261 0281

Adresse

2420 BRUNELLO TRACE, LUTZ

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

SCNX's Discussions on Twitter

Vergleichen Sie SCNX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SCNX Scienture Holdings Inc	1.4469	12.95M	0	0	0	0.00
WBA Walgreens Boots Alliance Inc	11.15	9.66B	147.66B	-8.64B	-363.00M	-10.01
WGRX Wellgistics Health Inc	4.31	224.40M	0	0	0	0.00
HITI High Tide Inc	1.985	152.97M	376.07M	-22.41M	18.73M	-0.298
PETS Petmed Express Inc	4.08	86.55M	270.52M	-6.08M	17.42M	-0.2944

Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten

Mar 26, 2025

Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register

Mar 26, 2025

Mar 25, 2025

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - The Manila Times

Mar 25, 2025

Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth - Stock Titan

Mar 25, 2025

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Manila Times

Mar 19, 2025

Organovo Announces Reverse Stock Split - The Manila Times

Mar 19, 2025

FDA Approves Revolutionary Liquid Losartan: Scienture's Game-Changing Hypertension Treatment - StockTitan

Mar 19, 2025

Mar 18, 2025

Scienture announces U.S. FDA approval of NDA for SCN-102 - TipRanks

Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Mar 18, 2025

FDA Approves Losartan Potassium for Reduction in Risk of Stroke - Drug Topics

Mar 18, 2025

What's Going On With Scienture Shares Tuesday? - Benzinga

Mar 18, 2025

FDA Approves SCN-102, Liquid Oral Suspension Formulation of Losartan - Pharmacy Times

Mar 18, 2025

Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light - Stocks Telegraph

Mar 18, 2025

Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan - Marketscreener.com

Mar 18, 2025

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - The Manila Times

Mar 18, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Mar 18, 2025

Breakthrough FDA Approval: First-Ever Liquid Hypertension Drug Targets $1.5B Market - StockTitan

Mar 18, 2025

Billionaires Ray Dalio and Paul Tudor Jones Are Piling Into a Hard Asset That Has Trounced Nvidia This Year - The Globe and Mail

Mar 18, 2025

Q4 Earnings Outperformers: D.R. Horton (NYSE:DHI) And The Rest Of The Home Builders Stocks - The Globe and Mail

Mar 18, 2025

Mar 17, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 17, 2025

4 Quantum Computing Stocks on Watch Today as GTC 2025 Kicks Off - The Globe and Mail

Mar 17, 2025

Mar 15, 2025